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Abstract: Western populations harbor a chronic inflammation pattern that lacks organ
cardinal signs (edema, increased temperature, pain, and impaired function), releases increased
levels of C-reactive protein, and often runs a creeping clinical course with generalized
debilitating disease superimposed on system-specific involvement, mostly including nervous
tissue (multiple sclerosis, Parkinson’s syndromes), joints (arthritis), and skin (psoriasis). A
finalistic interpretation may apply to the consideration of the gut as the source of inflammation.
In fact, these kind of local events as well as the remote manifestations named above, could be
conditioned by the microbiome, the huge cell population indwelling the gut which is under
growing scrutiny. The role of the gut as a barrier organ justifies lingering submucosal
inflammation as a patrolling activity to maintain bodily integrity; the microbiome, launching
inflammogenic signals in response to abrupt diet changes, confers to gut inflammation a
socioeconomic vector calling for hitherto unrecognized multi-disciplinary interventions.
Keywords: colorectal cancer, inflammation, inflammatory bowel disease, irritable bowel
syndrome, microbiome
Introduction
The last few years have witnessed a mounting interest for the phenomenon of
inflammation, with all aspects of pathology, mechanisms, and clinics becoming
reappraised closely. Rather than on classically known acute inflammation as an
ancestral defense reaction, our attention, in accord with many investigators,1,2 has
focused on its chronic manifestations. Roughly at the mid of the twentieth century,
the inhabitants of the Western World began to present with an increasing incidence
of (auto)immune disorders including arthritis, inflammatory bowel disease (IBD),
and neurodegenerative phenomena, such as Parkinson’s disease, multiple sclerosis,
amyotrophic lateral sclerosis, or Alzheimer’s disease. Suggesting a causative role
of expanding civilization, these phenomena have manifested as a full-blown
epidemic3 in some developing countries. Subjects attacked by this sort of creeping
inflammation typically presented with weight loss, fatigue, and inability to sustain a
productive life, deserving the fantasy label of “inflammacitizens”.4 Cutting-edge
studies on laboratory markers have recently found5 that the inflammacitizens
circulate abnormal levels of a marker named “GlycA”, which closely correlates
with other inflammatory indicators and, interestingly, may herald reduction in life
expectancy. The contemporary literature on chronic inflammation is abundant and
covers variegated aspects of both internal medicine and specialties; we have
arbitrarily chosen to succinctly expand on three publications dealing with both
general and particular issues related to chronic inflammation.
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Bennett et al,2 while covering and integrating the var-
iegated medical, immunological, and psychosocial aspects
of the individual’s interaction with the outer world, identi-
fied a few capital points listed below on a hypothetical
anti-inflammatory policy, in close accordance with our
recently published review:6
1. Prioritize policies designed to reduce the stress
impact on lifestyle, as stress poses lymphocytes
into a pro-inflammatory economy
2. Bear in mind the multi-systemic nature of pathobio-
logical events, whereby failure of one anti-inflam-
matory barrier can easily trigger malfunction of
other systems in a waterfall fashion
3. Organized teams of specialists should treat a multi-
system event such as inflammation
4. Better food choices and physical activity should be
prioritized
5. Stress management skills to activate the para-sym-
pathetic nerve system should be actively taught
6. Sleep quality should be at the top of caretakers’
attention.
The multidisciplinary approaches mentioned above
revealed7 that a sample student population undergoing
stressful examination or job competition may develop a
strong inflammation-like response, witnessed by increased
blood levels of conventional markers, such as erythrocyte
sedimentation rate and C-reactive protein. Such puzzling
finding has recently received a tentative behavioral
answer: in this context, inflammation could act as an
ancestral response to the threat to disrupt an individual’s
integrity, an equivalent to the ancestral fight between man-
kind and wilderness. Under these circumstances, inflam-
mation could be considered as a novelty in neuroscience.
In this context, in recent years the analysis of the gut-brain
axis is focusing on the role of microbiota as its mediator.
This axis would be bidirectional, being involved in the
pathogenesis of both primitively intestinal diseases such as
irritable bowel syndrome (IBS) and IBD, and of primi-
tively neurological diseases such as Parkinson’s disease,
Alzheimer’s disease, anxiety, depression, and autism. The
common factor in these pathologies appears to be dysbio-
sis, that is an alteration of the number and function of the
species of the microbiome. A reduction of bacterial buty-
rate-producing species results in a reduction of this short
chain fatty acid (SCFA) which is a lipid with local and
systemic anti-inflammatory characteristics.8
Finally, given the position of the gut as a barrier organ,
inflammation cannot be ignored in the field of gastroenterol-
ogy. Gastroenterologists repeatedly failed in their search for
the causes of IBS. Threshold levels of inflammatory cells in
the colonic biopsies have recently been found, suggesting
that intestinal inflammation is a continuum from mild IBS to
full-blown IBD.While this has been considered by some as a
leap forward in taxonomy, others have protested again the
total confusion that now seems to warrant immune suppres-
sion in an otherwise functional condition.9
The latter observation has advised us (as gastroenter-
ologists) to further review data banks, and to test whether
this point could enrich our concepts of inflammation.
Study concept
Henceforth, we shall: 1) dissect a few clinical conditions in
which a dominant role of inflammation has been recently
reiterated; 2) discuss the microbiome as the missing link
between gene and inflammation; 3) discuss the theoretical
and scientific consequences regarding disease classification;
and 4) assess whether the progress described above can
warrant a refinement of the current therapeutic options.
Articles published in English, on the inflammation as
dominant causative factor in several fields of gastroenterol-
ogy, were identified through MEDLINE, SCOPUS, ISI-
Web of Knowledge, and EMBASE searches. The search
of all studies published from January 1, 1988 to November
30, 2018 was conducted. The following medical subject
headings were used: “inflammation” associated with one
among “Irritable bowel syndrome”, colonic adenomas”,
“colorectal cancer”, “gluten sensitivity”, “microbiome”,
“microbiota”, “gut”, “bowel”, “IBD”, “inflammatory
bowel disease”, “ulcerative colitis”, “Crohn’s disease”,
“Helicobacter pylori”, “fecal microbiota transplantation”.
Reference lists from published articles were also employed.
Titles of the publications and their abstracts were scanned to
eliminate duplicates and irrelevant articles. Two authors
(G.C.A. and D.G.R.) independently reviewed the literature
search results and selected relevant studies. The full-text
studies were assessed by the two authors to determine
whether the inclusion criteria were met.
Recent studies on inflammation in clinical
entities
Irritable bowel syndrome
A recent paper (summarizing previous substantive evidence)
has confirmed a significant role of an inflammatory-immuno-
logical etiopathogenesis of IBS.10 This is supported by two
Ribaldone et al Dovepress
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evidences: 1) an increased mast-cell density and activity in
the IBS gut correlates with symptoms; 2) signs and symptoms
of persisting IBS are known to often follow episodes of
gastroenteritis.11,12 Indications to “eubiotic” treatments will
be discussed briefly in “Classification and theoretic issues”).
Role of inflammatory transcripts in colonic adenomas
and malignancy13
Evidence of the existence of inflammatory signals in colo-
nic polyps and their resolution in response to NSAIDs
have long been investigated by researchers. Recent studies
have now pinpointed to the fact that arachidonic acid
metabolism (cyclooxygenase-2 [COX-2] enzymes) link
prostaglandin metabolism and cancer, promoting angio-
genesis, cell growth, and invasion.14 Clinically, inhibition
of the COX-2 pathways, and detection of prostaglandin
signals in circulating cells may work as therapeutics and
non-invasive diagnostic markers, respectively.
The increasing prevalence of gluten sensitivity has
become a socio economic issue
The spectrum of gluten sensitivity disorders seems now to
span from traditional celiac disease, to atypical sero-nega-
tive celiac allergy, up to ill-defined neurological and even
autism-like manifestations.15 Typical elements of gut
inflammatory onset (increased immune cell infiltrates and
enhanced membrane permeability) seem to act as a
continuum among the various forms of gluten reaction
all the way to IBD.16,17
Linking the genetic message level with
inflammation: the microbiome
Dysbiosis as a common etiologic factor of several
diseases
Individuals live in a harmonious association with the gut
microbiome, with people giving the ideal condition to the
microbiota to thrive, and microscopic organisms conse-
quently breaking down the nourishment sugars to short
unsaturated fats, integrating certain nutrients and breaking
down dietary oxalates.18
A condition of alteration of the gut microbiome is
called “dysbiosis”, which in turn leads to an alteration of
the immune system homeostasis.
This condition is frequent in metabolic disorders, obe-
sity, IBS, IBD, allergy, asthma, cardiovascular diseases,
and infections (Figure 1).19,20
There are gaps in knowledge concerning the interaction
between the microbiome and the host as well as on the
consequences of this interaction.
Recent technological advancements in metabolomics
have vastly improved the sensitivity and accuracy at which
metabolites can be detected and characterized, and metabo-
lomic profiling might help answer these questions.21
Cardiovascular diseases
TMAO
IBS
Proinflammatory cytokines↑
Adiponectin↓
Adipose tissue
Asthma
Allergy
Irritable bowel syndrome
Metabolic disorders
Inflammatorv bowel
disease
Reduced diversity of the microbiota
(decrease of Firmicutes)
Decrease of SCFA-producing bacteria
(decrease of Clostridium cluster IV, XIVa, XVII
and Faecalibacterium prausnitzii)
Increase of mucolytic bacteria
(Ruminococcus gnavus)
Increase of sulfate-reducing bacteria
(Desulfovibro)
Increase Firmicutes (Streptococcus)
Increase Firmicutes (Streptococcus)
Increase Actinobacter
Increase Actinobacter
Dendritic
cell
Macrophage Unstable gut microbiota cause chronic gut dysfunction
Host factors
alter microbial
 habitat in gut
Unstable gut
microbiota contribute
  to unstable habitat 
Increase mucus production
Increase mucus permeability
Increase cytokines
Increase inflammatory cells
Increase Th17
T cell
B cell LCNeutrophil
Increase of Proteobacteria (Haemophilus, Klebsiella,
                                                   Neisseria, Moraxella)
Increase of Proteobacteria (Haemophilus, Klebsiella,
                                                   Neisseria, Moraxella)
Figure 1 Mechanisms of association between dysbiosis and various diseases.
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The case of IBD
In the bowel are present most of the immune cells of the
body, and only a single layer of columnar epithelial cells
physically divides the numerous luminal antigens from the
mucosal immune system. Microbial colonization impor-
tantly affects the immune system homeostasis.
Anomalous feedback between gut microbiome and the
immune system in the bowel mucosa has been recognized
as the central alteration that prompts chronic phlogosis.22
IBD is believed to be incited by an unduly aggressive
pattern of adaptive immune response mediated by T cells to
a subset of commensal enteric bacteria in genetically sus-
ceptible hosts. Several studies have demonstrated that the
activity phases of IBD are strongly associated with an over-
all increased prevalence of proteobacteria23 accompanied by
a drop in intestinal richness involving the phylum
Firmicutes,24 and the species Enterobacteriaceae,
Bacteroidales, and Clostridiales25 of Clades IV and XIVa.25
A lower number of butyrate-producing bacteria, such as
Clostridiales species, accounts for the reported reduction in
unsaturated fats in the stools of IBD patients. Butyrate serves
as a major source of energy for colonic epithelial cells and as
an inhibitor of pro-inflammatory cytokine expression in the
gut mucosa, through a mechanism that involves hyper-acet-
ylation of histones and suppression of the nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB)
signaling.26 Butyrate reinforces mucosal barrier function by
inducing production of mucin and antimicrobial peptides,
and by increasing epithelial barrier integrity through the
expression of tight junction proteins.27 Studies suggested a
link between IBD and a decreased prevalence of butyrate-
producing Faecalibacterium prausnitzii (firmicute), belong-
ing to Clostridia cluster IV species.28
Even though dysbiosis is firmly thought to be linked
with IBD, it is not clear whether this is a cause or a result
of the inflammatory process. Hence, there is a need for
prospective studies in healthy susceptible first-degree rela-
tives of IBD patients, evaluating genetic, environmental
and microbial factors, to clarify whether changes in the
microbial communities precede or follow IBD onset.
The role of the diet
Differences in diet seem to be a factor that could impact
synthesis of butyrate in the gut, impairing the composition
of microbiome.
Compared with healthy controls, Crohn’s disease (CD)
patients intake less vegetable and fruit, and more pro-
cessed bread (white bread), and sugar foods. Patients
with CD and a high number of butyrate-producing bacteria
had a larger intake of nuts than those with a reduction in
butyrate-producing bacteria. CD patients with a reduction
in butyrate-producing bacteria intake less amount of cer-
tain foods containing fibers such as whole wheat, cereals,
fruits, vegetables, and nuts, and increased intake of high
non-whole wheat and sugar-rich foods. This proposes that
microbiome modulation, either accomplished by probiotics
or by prebiotics, may give increase more efficiently buty-
rate levels in the bowel respect to mere intake of butyrate
itself.29
Prebiotics are non-edible sugars, for example, fiber and
starch, which are broken down in the jejunum and the
ileum by local bacteria. So, dietary fiber is a wellspring
of microbiota available starches. Wellsprings of prebiotics
incorporate inulins, soybeans, whole grain and wheat,
crude oats, and non-edible oligosaccharides, for example,
fructooligosaccharides (FOS), polydextrose, fructans, ara-
binooligosaccharides (AOS), xylooligosaccharides (XOS),
and galactooligosaccharides (GOS).30 Non-absorbable
sugar-rich diets (ie, whole wheat and grain) are connected
to an expansion in gut Lactobacilli and Bifidobacteria.31
The positive impact of prebiotics on the bowel is thought
to include a higher production of SCFAs.30
Polyphenols of the diet (ie, flavonols, catechins,
proanthocyanidins, flavones, phenolic acids, and anthocya-
nins) are reported for their cancer prevention agent proper-
ties. Typical nourishments with rich polyphenol content
incorporate natural products, vegetables, seeds, cocoa
items, wine, and tea.30,32
In a recent meta-analysis curcumin, a biologically
active phytochemical, with its unique anti-oxidant and
anti-inflammatory activities and ability to modulate gut
microbiota, resulted a potentially useful addition to our
armamentarium of agents for IBS.33 It also appeared safe
and well tolerated, with no adverse events reported in the
available trials.
The effort to reduce inflammation in gastrointestinal dis-
orders
Cutting-edge research conducted in the last few months
has placed a doubly committed attention on the role played
by intestinal bacteria in causing or perpetuating IBD:
bioremediation has been addressed by specifically investi-
gating the effects of 5-aminosalicylic acid (5-ASA) com-
pounds on gut microflora diversity and composition and in
relation with the clinical response.34 It was found that
5-ASA exerted a beneficial effect on these parameters,
Ribaldone et al Dovepress
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favoring the establishment of a remission picture. Closer
insights revealed that mucosal 5-ASA concentrations were
positively associated with bacterial diversity; high mucosal
drug concentrations correlated with a drop of harmful
species concentrations (Proteobacteria) and increased
abundance of favorable species such as Fecalibacterium.
Taken together, these data so far indicated that diet
composition and use of drugs of the 5-ASA family can
be effective to downregulate gastrointestinal inflammation
in various disease contexts.
The gene-cytokine level
It is well known that genetic predisposition is involved
in the onset of IBD. To date, over 230 genetic loci have
been identified as associated with an increased risk of
developing IBD. Most of the genes involved in the
pathogenesis of IBD have a defense role against intest-
inal bacteria, including a protein related to autophagy
16–1 (ATG16L1), the IL-10 receptor and the receptor of
the IL-23.35
The nucleotide-binding oligomerization domain-like
receptors are a group of intracellular, highly conserved,
receptors that recognize a signal of infections, through
inflammasome cascades, NF-κB, and mitogen-activated
protein kinase signaling.36,37 In patients with IBD there is
a defect in recognition of infections.38 So, innate immune
response would be involved in the pathogenesis of CD.
Furthermore, a less level of tolerance to the normal bowel
microbiome seems to play a pivotal role in IBD etiology.39
Autophagy is also involved, through ATG16L1 gene, favor-
ing the entrance of the bacteria in the cells (Table 1).40
Classification and theoretic issues
The case of Helicobacter pylori (H. pylori)
The presence of an inflammatory adjunct to any pathogen
can break the boundaries of the niche where it thrived,
hence allowing trans-organ pathogenicity. This is the case
of H. pylori. In addition to being unanimously recognized
as the cause of gastritis and peptic ulcer (PU) disease,41
this bacterium, from its gastric niche, through the forma-
tion of inflammatory immune-toxin complexes has been
shown to be involved in vasculitides affecting as dispa-
rate districts as the nervous system and the cardiac
vessels.42 Recently, an updated review on H. pylori as
one major factor triggering sporadic (non-genetic)
Parkinson’s disease has been published.43 The extra-gas-
tric manifestations of H. pylori may also be caused by a
chronic, low-grade inflammation, induced by this bacter-
ium, resulting in an increase in cytokines levels such as
tumor necrosis factor (TNF)-α, IL-1, IL-6, IL-8, γ inter-
feron and soluble molecules like intercellular adhesion
molecule (ICAM-1) and vascular cell adhesion molecule
(VCAM-1).44 In an interesting study,45 high-sensitivity
assay C-reactive protein resulted higher in H. pylori-
infected PU patients than in H. pylori-infected asympto-
matic carriers or in uninfected subjects, likely through a
cytokines-mediated mechanism (IL-1, IL-6, IL-8,
TNF).46,47
Regarding the extra-gastric manifestation of H. pylori
infection, for example, it is assumed that the gastric coloni-
zation with this bacterium is related with a higher probability
of hyperemesis gravidarum, with a pooled OR of 1.3
(p<0.001).48 The changes of the woman body during preg-
nancy include a diminished cell-mediated immunity, subse-
quently making her progressively inclined to infections, such
as a reactivation of a previous H. pylori infection.49 The
gastric inflammation induced by H. pylori increases the
typical nausea and vomiting in hyperemesis gravidarum.50
The finding of H. pylori in a woman suffering from hyper-
emesis gravidarum gives to this patient the possibility (treat-
ing the infection after the pregnancy) to prevent her
symptoms in a future new pregnancy.
Table 1 Main genes involved in inflammatory bowel diseases
Gene Disease Function
ATG16L1 CD Autophagy
IL-10R VEO-IBD Inhibits the release of several cytokines and have an anti-inflammatory effect in the gastrointestinal tract
IL-23R IBD IL-23 target cells such as T helper 17 cells, innate lymphoid cells type 3, granulocytes and natural killer cells increase
production of proinflammatory cytokines
NLRs IBD Receptors that recognize a signal of infections, through an inflammasome cascades, NF-κB and mitogen-activated protein
kinase (MAPK) signaling
Abbreviations: ATG16L1, autophagy related 16 like 1; CD, Crohn’s disease; VEO-IBD, very early onset inflammatory bowel disease; NLRs, nucleotide-binding oligomeriza-
tion domain (NOD)-like receptors; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells.
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The epithelial barrier
With a wall formed by an epithelium and a lymphocyte-
rich sub-epithelium, and a lumen indwelled by billions of
germs (the microbiome), the gut is now classified as a
barrier organ:51 the integrity of the latter function depends
on the maintenance of the sealing status of the mucosa and
the submucosa. The equilibrium of the system depends on
the regulation of a subliminal lingering inflammation:
infections, drugs, tobacco, psychological stress52 are but
a few of the agents that can alter the sealing status men-
tioned above and let the luminal contents53 arouse the
indwelling lymphocytes to tip the balance. It is not diffi-
cult to envisage that perturbation of this machinery makes
a continuum of severity gradient ranking from (simple)
IBS to the severest IBD, with consequent erosions of
epithelial barrier being not always welcomed.9 The prac-
tical consequences of these etiopathogenetic mechanisms
on therapeutic options will be dissected below.
Implications: treat-to-target strategies?
The concept of treat-to-target strategies was borrowed
from rheumatologists,54 foreseeing that the natural history
of rheumatic patients could be changed if they would be
treated with strategies focused to identify pathological
targets (for example, cartilage erosions) than toward gen-
eric clinical goals such as physical performance or well-
being. The identification of pathological targets in IBD
(for example, calprotectin under 250 µg/g or mucosal
healing)55,56 favored the translation to gastroenterology
of this rheumatologic frame of mind.
Several hints for a role of infectious pathogens in IBS
warrant the pragmatic use of cycles of antibiotics followed
by repopulation with “eubiota”; the evidence of inflamma-
tory transcripts in gut polyps suggests the potential useful-
ness of the treatments with NSAIDs; suspicions of an
enlarged pathogenic role of gluten proteins provide indica-
tions for tentative exclusion of gluten from the diets of
otherwise seronegative individuals.
On the other hand, the search for inflammatory mar-
kers in colonic disorders can easily raise concerns
regarding doctor–patient relationship. For instance, pre-
scription of the anti-inflammatory aminosalycilic acid
(5-ASA) can make an IBS patient believe that the diag-
nosis of full-blown IBD had been originally missed;
moreover, UC patients, if offered to participate in a
trial with the anti-STAT molecule tofacitinib,57 may
suspect being offered a modern expensive version of a
cortisone drug.
Finally, the discovery of the pivotal role of the
microbiota in inflammatory diseases brought about an
increasing number of studies regarding the efficacy of
fecal microbiota transplantation (FMT) in intestinal and
extra-intestinal diseases.58 In the randomized controlled
trial conducted by Moayyedi et al,59 the authors found
that early diagnosis of UC might result in better out-
comes after FMT. This suggests a potential window of
opportunity for FMT after diagnosis of UC.
Accordingly, Paramsothy et al60 suggested that less
severe grades of endoscopic inflammation may be a
potential predictor of FMT response. Moreover, the
increase of Clostridium clusters IV and XVIII and the
high microbial diversity were identified as predictors of
FMT efficacy. Conversely, the presence of Sutterella
spp. and Fusobacterium spp. was associated with non-
response to FMT.
Concluding remarks
In the environment of a “barrier organ” like the gut,
inflammation can easily acquire specific significance.
Potent scrutiny by modern techniques tends to blur the
limits originally established between functional and
organic disorders: mapping of the inflammatory patterns
tends rather to delineate a disease continuum with an
impact on therapeutic choices.61
Study highlights
What is current knowledge
The IBDs have been known for a century as inflammatory
disorders hitting the gut at variable frequencies, and trig-
gered by undefined factors, although an erratic response to
antibiotics has at times refueled the quest for infectious
origin. Prevalently positive results achieved by immune
suppressive strategies have continued to fuel interest on
the indications for steroids, then for immune suppression,
culminated in the use of anti-cytokine monoclonals.
What is new here
The early decades of the twentieth century have witnessed
an epidemic-like expansion of the IBDs hitting mostly
developing countries and/or migrant populations from
low-income to high-income areas of the world.
Dissection of the elements in this apparently IBD-trigger-
ing Western life drew attention on factors such as diet
(turned to a high elaborated protein and low fiber content);
competitive work often carried out on night-shift, noise
and artificial light pollution as hallmarks of a city life as
Ribaldone et al Dovepress
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opposed to often deserted countryside.62 The variegated
etiologic array of IBD, wherein concrete factors such as
genetics and diet mix up with the dynamics of psychology,
namely working rhythms, noise, and artificial lights, is far
from being understood in an organic way. The main points
in the title (eg, the socio economic factors of IBD) begin
here to shape up, heralding the final choral stage where the
appearance on the scene of the microbiome (sub-title: what
is new here) opens new perspectives in this field.
Inflammation was soon recognized as a protagonist,
with at least a couple of novelties. It manifested as a
creeping phenomenon lacking the known cardinal signs
of the acute inflammatory bouts of the past century, and
became the obviously leading pathology of hyperimmune
diseases, ranging from rheumatoid arthritis to degenerative
neuropathies.
IBD was easily positioned among this “modern” dis-
ease pattern, receiving a sort of “mark of the times”
hitherto not clearly evaluated.
Yet, the specific variable that contributed to make IBD
a disorder of the times was the microbiome. This huge bug
colonic population is an example of mutual synergy. While
the gut provides a uniquely suited environment, the micro-
biome components exert multiplex functions including
inhibition of pathogenic bacteria, absorption of nutrients,
regulation of the intestinal immune system, and control of
cell renewal.
The key point is that the microbiome is a functional
signal mediator, with a recorder end tuned to the environ-
ment, and an effector terminal capable to translate outside
signals into modulating actions directed to the gut immune
response. In this way, the immune gut cell environment is
made to change accordingly and synchronously with the
outside where diet components can be the primary drivers
of change. Having set that the intestinal immune environ-
ment can preferentially respond to the diet through the
“transponder” action of the microbiome, we can say that
gut inflammation may chiefly respond to socio economic
factors of which the diet is one of the primary probes.
Connectivity may be the best definition for this novel
network set forth by the microbiome.
This novel frame of mind offers therefore at least two
materialized targets to work on (feeding habits and working
rules), and calls on a huge number of social categories to
lend their help and know-how toward a changing pathway.
Thus, basic science knowledge and experience from real
life are conducting us to merge with the holistic visions
brought about by those interested in science forecast.63
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